| Identification | Back Directory | [Name]
JNJ-10397049 | [CAS]
708275-58-5 | [Synonyms]
JNJ-10397049
JNJ-10397049, CID 9869934
JNJ 10397049; JNJ10397049
3-(2,4-DIBROMOPHENYL)-1-[(4S,5S)-2,2-DIMETHYL-4-PHENYL-1,3-DIOXAN-5-YL]UREA
1-(2,4-dibromophenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-1,3-dioxan-6-yl)urea
1-(2,4-dibromophenyl)-3-[(4S,5S)-2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl]urea
N-(2,4-DIBROMOPHENYL)-N'-[(4S,5S)-2,2-DIMETHYL-4-PHENYL-1,3-DIOXAN-5-YL]-UREA
Urea, N-(2,4-dibromophenyl)-N'-[(4S,5S)-2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl]- | [Molecular Formula]
C19H20Br2N2O3 | [MDL Number]
MFCD17170315 | [MOL File]
708275-58-5.mol | [Molecular Weight]
484.18 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
Soluble to 100 mM in DMSO and to 100 mM in ethanol | [form ]
Powder | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
JNJ 10397049 is a selective OX2 receptor antagonist that exhibited sleep promoting effects in rats. | [in vivo]
JNJ-10397049 (10-30 mg/kg) decreases the latency for persistent sleep and increased nonrapid eye movement and rapid eye movement sleep time[2].
JNJ-10397049 blocks ethanol self-administration, place preference and reinstatement[3].
| Animal Model: | Male Sprague-Dawley rats[2]. | | Dosage: | 10 mg/kg. | | Administration: | Subcutaneous administration. | | Result: | Induced a significant reduction in NREM sleep latency and an increase in NREM sleep duration during the first 2 h after administration relative to vehicle treatment.
|
| [IC 50]
OX2 Receptor | [storage]
Store at +4°C |
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|